Loading…
Foghorn Therapeutics Inc. is projected to decline to $4.24 by 2027, a -1% move from its current price of $4.27. FHTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.11 | $4.27 | $4.43 | -0.08% |
| May 30 | $4.04 | $4.26 | $4.50 | -0.16% |
| May 31 | $3.99 | $4.26 | $4.55 | -0.24% |
| Jun 1 | $3.95 | $4.26 | $4.59 | -0.32% |
| Jun 2 | $3.91 | $4.25 | $4.62 | -0.40% |
| Jun 3 | $3.88 | $4.25 | $4.66 | -0.48% |
| Jun 4 | $3.85 | $4.25 | $4.69 | -0.56% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.85 | $4.25 | $4.69 | -0.56% |
| Week 2 | $3.67 | $4.22 | $4.86 | -1.12% |
| Week 3 | $3.54 | $4.20 | $4.98 | -1.68% |
| Week 4 | $3.42 | $4.17 | $5.09 | -2.23% |
| Week 5 | $3.33 | $4.15 | $5.18 | -2.78% |
| Week 6 | $3.24 | $4.13 | $5.26 | -3.32% |
| Week 7 | $3.16 | $4.10 | $5.34 | -3.87% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. It uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
The company is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. It has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM.
Foghorn Therapeutics was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Foghorn Therapeutics Inc. (FHTX) is a Healthcare stock currently trading at $4.22 per share with a market cap of $247.77M. It is ranked 3677 in market capitalization.
The near-term price action carries a bearish tone given the current technical setup, while the longer-term forecast shows a bullish trajectory beginning in 2030. This sets up a potential multi-year upside, with the forecast extending into the 2030s and beyond.
A major floor 40.3% below — a decisive break under it would weaken the trend.
The nearest floor, 15.7% below — buyers have tended to step in here.
The nearest ceiling, 29.0% above — a clean break opens room to run.
A major ceiling 49.2% above — clearing it would confirm fresh momentum.
Key FHTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FHTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.20 | Buy | $4.20 | Buy |
| MA 10 | $4.04 | Buy | $4.18 | Buy |
| MA 20 | $4.30 | Sell | $4.32 | Sell |
| MA 50 | $4.69 | Sell | $4.65 | Sell |
| MA 100 | $5.16 | Sell | $4.86 | Sell |
| MA 200 | $4.96 | Sell | $4.97 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.35 | Neutral |
| Stoch RSI (14) | 89.81 | Sell |
| CCI (20) | -6.31 | Neutral |
| Williams %R (14) | -20.24 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | -3.83 | Sell |
| Bollinger %B (20,2) | 0.48 | Neutral |
| Stochastic %K (14) | 79.76 | Neutral |
| TRIX (15) | -0.74 | Sell |
| Awesome (5,34) | -0.41 | Sell |
| Ultimate (7,14,28) | 58.97 | Neutral |
| Momentum (10) | 0.03 | Buy |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 4.39 | Sell |
| ADX (14) | 20.26 | Sell |
| ATR (14) | 0.15 | Info |
The 30-day technical picture is Bearish with RSI14 at 40. The stock is trading below the SMA50 of $4.72 and the SMA200 of $4.96, signaling potential weakness.
Key support is at $3.60 and resistance at $5.51, framing possible moves within these levels. The 30-day range spans from $3.27 to $5.45.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.60 | $4.27 | $5.69 | 0% | Neutral | |
| $3.24 | $4.24 | $5.94 | -1% | Neutral | |
| $3.07 | $4.18 | $6.14 | -2% | Neutral | |
| $3.24 | $4.55 | $6.92 | +7% | Neutral | |
| $4.08 | $5.90 | $9.27 | +38% | Bullish | |
| $4.25 | $6.32 | $10.19 | +48% | Bullish | |
| $4.15 | $6.33 | $10.44 | +48% | Bullish | |
| $4.38 | $6.85 | $11.55 | +60% | Bullish | |
| $4.00 | $6.40 | $11.01 | +50% | Bullish | |
| $3.97 | $6.50 | $11.38 | +52% | Bullish | |
| $5.09 | $9.24 | $17.45 | +116% | Bullish | |
| $7.44 | $16.32 | $34.38 | +282% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.60 | $4.27 | $5.04 | +0.00% |
| June 2026 | $3.53 | $4.18 | $5.10 | -1.99% |
| July 2026 | $3.31 | $3.97 | $4.92 | -5.19% |
| August 2026 | $3.33 | $4.02 | $5.06 | +1.33% |
| September 2026 | $3.45 | $4.20 | $5.34 | +4.39% |
| October 2026 | $3.40 | $4.16 | $5.35 | -0.78% |
| November 2026 | $3.36 | $4.15 | $5.37 | -0.45% |
| December 2026 | $3.51 | $4.35 | $5.69 | +4.99% |
Click any year to see its month-by-month FHTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Foghorn Therapeutics Inc.'s 2026 outlook centres on $4.27, within a $3.60 to $5.69 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, FHTX could reach as high as $5.94, with a base case around $4.24 and support toward $3.24 — roughly -1% from $4.27. Price action looks broadly range-bound.
Expect FHTX to range from $3.07 to $6.14 through 2028. The $4.18 average target implies a -2% move from current prices. That is -1% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The FHTX price prediction for 2029 points to an average of $4.55 (low $3.24, high $6.92) — a potential gain of +7% on today's $4.27. Price action looks broadly range-bound.
In 2030, FHTX is projected to trade between $4.08 and $9.27, averaging $5.90 — a potential gain of +38% from today's $4.27. That is up +30% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Foghorn Therapeutics Inc.'s 2031 outlook centres on $6.32, within a $4.25 to $10.19 range. That is up +7% on the projected 2030 average. That marks a +48% change versus current levels. Momentum favours further upside here.
By 2032, FHTX could reach as high as $10.44, with a base case around $6.33 and support toward $4.15 — roughly +48% from $4.27. Buyers look set to stay in control over this stretch.
Expect FHTX to range from $4.38 to $11.55 through 2033. The $6.85 average target implies a +60% move from current prices. That is up +8% on the projected 2032 average. Momentum favours further upside here.
The FHTX price prediction for 2034 points to an average of $6.40 (low $4.00, high $11.01) — a potential gain of +50% on today's $4.27. Buyers look set to stay in control over this stretch.
In 2035, FHTX is projected to trade between $3.97 and $11.38, averaging $6.50 — a potential gain of +52% from today's $4.27. That is up +1% on the projected 2034 average. Momentum favours further upside here.
Foghorn Therapeutics Inc.'s 2040 outlook centres on $9.24, within a $5.09 to $17.45 range. That is up +42% on the projected 2035 average. That marks a +116% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, FHTX could reach as high as $34.38, with a base case around $16.32 and support toward $7.44 — roughly +282% from $4.27. Momentum favours further upside here.
Investing $1,000 in FHTX today (≈ 234.192037 FHTX) could be worth
$3,821.71
+$2,821.71 (+282%) by 2050 · US Dollar
Based on the average projected FHTX price of $16.32 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FHTXwould be worth at today's price.
$1,000 invested in FHTX on May 27, 2025 (≈ 246.913569 FHTX) would be worth
$1,054.32
+$54.32 (+5.4%) today · 1.05× · US Dollar
Based on a FHTX entry price of $4.05 vs. today's $4.27.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4 | $1,067.5 | +6.7% |
| 1 month ago | $5.21 | $819.58 | -18.0% |
| 3 months ago | $5.76 | $741.32 | -25.9% |
| 6 months ago | $4.75 | $898.95 | -10.1% |
| 1 year ago | $4.05 | $1,054.32 | +5.4% |
| All time (5.0y) ago | $11.15 | $382.96 | -61.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FHTX forecast.
Our base-case forecast reaches $8.50 around 2040.
Implied market cap at $8.50: $499.07M
The multi-year forecast shows a shift from neutral to bullish in 2030 and beyond. For 2026, the min/avg/max are $3.60/$4.22/$5.67 with ROI 0 and sentiment Neutral. In 2027 the range is $3.11/$4.09/$5.77 with ROI -3.1 and Neutral; 2028 shows $2.95/$4.05/$5.99 with ROI -4.1 and Neutral; 2029 shows $3.11/$4.40/$6.76 with ROI 4.3 and Neutral.
From 2030 onward, the average price rises to $5.63 with a max of $8.92 and ROI 33.3% (Bullish). In 2031 the avg is $6.08 with ROI 44.1%; 2032 is $6.10 with ROI 44.5%; 2033 is $6.53 with ROI 54.6%; 2034 is $6.10 with ROI 44.6%; 2035 is $6.15 with ROI 45.8% (Bullish).
The 2040 forecast shows an average of $8.71 with a max of $16.68 and ROI 106.3% (Bullish); the 2050 forecast shows an average of $15.25 with a max of $32.67 and ROI 261.4% (Bullish).
These are estimates and carry uncertainty. The long-run outlook turns bullish from 2030 onward, with higher expected averages and ROIs, but near-term results remain mixed.
Tap a question to reveal the answer.
2030 min $3.85, avg $5.63, max $8.92; ROI 33.3%; sentiment BULLISH.
The forecast turns bullish from 2030 onward with rising averages and ROIs: 2030 avg $5.63 (ROI 33.3%), 2040 avg $8.71 (ROI 106.3%), and 2050 avg $15.25 (ROI 261.4%), though earlier years (2026–2029) show neutral or modest results.
Yes. The 2040 max is $16.68, while the 2040 average is $8.71, indicating that reaching $15 by 2040 would be within the forecast range.
Current price is $4.22 and market cap is $247.77M.
2050 min $6.86, avg $15.25, max $32.67; ROI 261.4%; sentiment BULLISH.
Foghorn Therapeutics Inc. Community Discussion
0Share your Foghorn Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.